NervGen Pharma is no longer a Canadian venture listing waiting on a proof-of-concept readout. It is a Nasdaq-listed, still-pre-revenue British Columbia issuer whose entire equity story now sits on whether a twenty-person chronic spinal cord injury signal survives a single registrational study. The May financing and the April agency alignment moved the company from asking whether the peptide does anything to asking whether the organization can enroll and run a late-stage trial without another rescue raise. That is a narrower and more expensive question, and the tape is treating it as such.
The tension is not whether chronic tetraplegia is an empty commercial field. There is still no approved pharmacologic therapy that restores function years after injury, and the CONNECT chronic cohort produced a coherent bundle of electrophysiology, hand-function trends, bladder and spasticity reports, and later independent gait mechanics. The problem is scale and endpoint choice. The mid-stage primary that cleared the bar was a hand-muscle electrical signal. The registrational primary is a graded hand-function scale that only trended in the same twenty-person study. A reader who treats CONNECT as a miniature RESTORE is reading more certainty than the statistics support.
Cash after the unit offering is enough, on management's plan, to reach the first-half twenty twenty-eight topline, and the new at-the-market facility remains unused. The same quarter booked a large non-cash warrant revaluation and left a warrant stack that can still reprice the residual claim. The question the next several quarters resolve is operational rather than scientific: whether screening starts on the September timetable, and whether enrollment looks like a study that can actually finish.